B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy

¹ Departments of ¹Urology, ²Health Sciences Research, ³Immunology, and ⁴Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

^* To whom correspondence should be addressed. E-mail: kwon.eugene{at}mayo.edu.

	Abstract

B7 coregulatory ligands can be aberrantly expressed in human disease. In the context of cancer, these ligands may act as antigen-specific inhibitors of T-cell–mediated antitumoral immunity. We recently reported that B7-H1 expression by carcinomas of the kidney and bladder portends aggressive disease and diminished survival. The expression of these proteins in prostate cancer, however, has not been investigated. We evaluated B7-H3 and B7-H1 protein expression in the pathologic specimens of 338 men treated for clinically localized prostate cancer between 1995 and 1998 with radical retropubic prostatectomy. Expression levels of B7-H3 in prostate cancer were correlated with pathologic indicators of aggressive cancer as well as clinical outcome. We report that B7-H3 is uniformly and aberrantly expressed by adenocarcinomas of the prostate, high-grade prostatic intraepithelial neoplasia, and four prostate cancer cell lines, whereas B7-H1 is rarely expressed. B7-H3 is expressed by benign prostatic epithelia, although at a more reduced level relative to neoplastic tissue. Increasing levels of B7-H3 intensity correlate with worsening clinicopathologic features of prostate cancer. Marked B7-H3 intensity, present in 67 (19.8%) specimens, confers a >4-fold increased risk of cancer progression after surgery (risk ratio, 4.42; P < 0.001). A survey of normal tissues revealed that B7-H3 is expressed within the liver, urothelium, and fetal kidney. In summary, B7-H3 is aberrantly expressed in all prostate cancers and represents an independent predictor of cancer progression following surgery. Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well. [Cancer Res 2007;67(16):7893–900]

Key Words: Costimulation, B7-H1, Genitourinary cancers: prostate, Immunology, Immunomodulation, Molecular markers of metastasis and progression

This article has been cited by other articles:

				H. Xu, I. Y. Cheung, H.-F. Guo, and N.-K. V. Cheung MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors Cancer Res., August 1, 2009; 69(15): 6275 - 6281. [Abstract] [Full Text] [PDF]

				I. Mercier, M. C. Casimiro, J. Zhou, C. Wang, C. Plymire, K. G. Bryant, K. M. Daumer, F. Sotgia, G. Bonuccelli, A. K. Witkiewicz, et al. Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-Like Mammary Lesions Am. J. Pathol., April 1, 2009; 174(4): 1172 - 1190. [Abstract] [Full Text] [PDF]

				G. Chavin, Y. Sheinin, P. L. Crispen, S. A. Boorjian, T. J. Roth, L. Rangel, M. L. Blute, T. J. Sebo, D. J. Tindall, E. D. Kwon, et al. Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases Clin. Cancer Res., March 15, 2009; 15(6): 2174 - 2180. [Abstract] [Full Text] [PDF]

				B. D. Lehmann, M. S. Paine, A. M. Brooks, J. A. McCubrey, R. H. Renegar, R. Wang, and D. M. Terrian Senescence-Associated Exosome Release from Human Prostate Cancer Cells Cancer Res., October 1, 2008; 68(19): 7864 - 7871. [Abstract] [Full Text] [PDF]

				P. L. Crispen, Y. Sheinin, T. J. Roth, C. M. Lohse, S. M. Kuntz, X. Frigola, R. H. Thompson, S. A. Boorjian, H. Dong, B. C. Leibovich, et al. Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., August 15, 2008; 14(16): 5150 - 5157. [Abstract] [Full Text] [PDF]

				S. A. Boorjian, Y. Sheinin, P. L. Crispen, S. A. Farmer, C. M. Lohse, S. M. Kuntz, B. C. Leibovich, E. D. Kwon, and I. Frank T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival Clin. Cancer Res., August 1, 2008; 14(15): 4800 - 4808. [Abstract] [Full Text] [PDF]

				M. Hashiguchi, H. Kobori, P. Ritprajak, Y. Kamimura, H. Kozono, and M. Azuma From the Cover: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses PNAS, July 29, 2008; 105(30): 10495 - 10500. [Abstract] [Full Text] [PDF]

				K. A. Hofmeyer, A. Ray, and X. Zang The contrasting role of B7-H3 PNAS, July 29, 2008; 105(30): 10277 - 10278. [Full Text] [PDF]

				X. Zang, R. H. Thompson, H. A. Al-Ahmadie, A. M. Serio, V. E. Reuter, J. A. Eastham, P. T. Scardino, P. Sharma, and J. P. Allison B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome PNAS, December 4, 2007; 104(49): 19458 - 19463. [Abstract] [Full Text] [PDF]